Hepatitis B Virus and Tuberculosis Are Associated with Increased Noncommunicable Disease Risk among Treatment-Naïve People with HIV: Opportunities for Prevention, Early Detection and Management of Comorbidities in Sierra Leone
Authors:
- George A. YendewaGeorge A. Yendewa
- Sulaiman LakohSLSulaiman Lakoh
- Darlinda F. JibaDJDarlinda F. Jiba
- Sahr A. YendewaSYSahr A. Yendewa
- Umu BarrieUBUmu Barrie
- Gibrilla F. DeenGDGibrilla F. Deen
- Mohamed SamaiMSMohamed Samai
- Jeffrey M. JacobsonJJJeffrey M. Jacobson
- Foday SahrFSFoday Sahr
- Robert A. SalataRSRobert A. Salata
Open Access
- 16 June 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (12) , 3466
Abstract
Noncommunicable diseases (NCDs) are a growing public health concern in low- and middle-income countries and disproportionately affect people living with HIV (PWH). Hepatitis B virus (HBV) and tuberculosis (TB) coinfection are presumed risk factors in endemic settings; however, supporting evidence is conflicting. We analyzed baseline data of newly diagnosed PWH prospectively enrolled in the Sierra Leone HIV Cohort Study in Freetown, Sierra Leone, from March to September 2021. Logistic regression was used to identify associations between NCDs, HBV and TB. A total of 275 PWH aged ≥18 years were studied (55% female, median age 33 years, median CD4 307 cells/mm3, 15.3% HIV/HBV, 8.7% HIV/TB). NCDs were bimodally distributed, with 1 in 4 PWH clustered around liver disease (fibrosis/cirrhosis), diabetes/prediabetes and obesity/preobesity, while 1 in 8 had renal impairment or hypertension (HTN). Overall, 41.5% had ≥1 NCD, while 17.5% were multimorbid (≥2 NCDs). After adjusting for age, sex, sociodemographic factors and CD4 count, liver fibrosis/cirrhosis was strongly associated with HBV (aOR 8.80, 95% CI [2.46–31.45]; p < 0.001) and diabetes/prediabetes (aOR 9.89, 95% CI [1.14–85.67]; p < 0.037). TB independently predicted diabetes/prediabetes (aOR 7.34, 95% CI [1.87–28.74]; p < 0.004), while renal impairment was associated with proteinuria (aOR 9.34, 95% CI [2.01–43.78]; p < 0.004) and HTN (aOR 6.00, 95% CI [1.10–35.39]; p < 0.049). Our findings warrant the implementation of NCD-aware HIV programs for the prevention, early detection and management of comorbidities.Keywords
Funding Information
- National Institutes of Health (NIH)/AIDS Clinical Trials Group (ACTG) (5UM1AI068636-15, 5UM1AI069501-09, J0713, P0603)
- Roe Green Center for Travel Medicine (5UM1AI068636-15, 5UM1AI069501-09, J0713, P0603)
- University Hospitals Minority Faculty Career Development Award/University Hospitals Cleveland Medical Center (5UM1AI068636-15, 5UM1AI069501-09, J0713, P0603)
This publication has 67 references indexed in Scilit:
- Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and ManagementJournal of Clinical and Experimental Hepatology, 2013
- Risk of type 2 diabetes among HIV-infected and healthy subjects in ItalyEuropean Journal of Epidemiology, 2012
- APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated NephropathyJournal of the American Society of Nephrology, 2011
- Mechanisms of hepatic fibrogenesisBest Practice & Research Clinical Gastroenterology, 2011
- Performance of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Staging of Hepatitis C-Related Fibrosis: An Updated Meta-Analysis §ΔHepatology, 2010
- Comparison of Elastography, Serum Marker Scores, and Histology for the Assessment of Liver Fibrosis in Hepatitis B Virus (HBV)-Infected Patients in Burkina FasoThe American Journal of Tropical Medicine and Hygiene, 2010
- HIV infection and the risk of diabetes mellitusAIDS, 2009
- The role of adipokines in liver fibrosisPathophysiology, 2008
- Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral TherapyCirculation, 2008
- Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis BAIDS, 2007